Abstract
Priming rare subdominant precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against HIV. Multivalent immunogen display on protein nanoparticle scaffolds can promote such responses, but it also generates scaffold-specific B cells that could theoretically limit bnAb precursor expansion in GCs. We rationally designed DNA origami–based virus-like particles (DNA-VLPs) displaying a germline-targeting HIV envelope protein immunogen, which elicited no scaffold-specific antibody responses. Compared with a state-of-the-art clinical protein nanoparticle, these DNA-VLPs increased the expansion of epitope-specific GC B cells relative to off-target B cells and enhanced expansion of bnAb-lineage B cells in a humanized mouse model of CD4 binding site priming. Thus, minimizing off-target responses enhances bnAb priming and indicates that DNA-VLPs are a promising vaccine platform.
All Related Versions
Funding Information
  • National Institutes of Health (P30-ES002109)
  • National Institutes of Health (R01-AI162307-03)
  • National Institutes of Health (R01-AI153098)
  • National Institutes of Health (AI144462)
  • Howard Hughes Medical Institute
  • National Cancer Institute (P30-CA14051)
  • Bill and Melinda Gates Foundation (NAC INV-007522)
  • Bill and Melinda Gates Foundation (INV-008813)
  • Bill and Melinda Gates Foundation (INV-034657)
  • National Science Foundation Fellowship (4000168384)
  • Novo Nordisk Fonden (NNF23OC0082848)
  • National Science Foundation Fellowship (4000189657)

This publication has 98 references indexed in Scilit: